Satellos Secures Nasdaq Listing, Funding to Propel Novel DMD Drug into Key Trials

TORONTO, ON – March 27, 2026 – Clinical-stage biotechnology firm Satellos Bioscience Inc. has made a significant leap forward, securing a major equity financing and a coveted Nasdaq listing to fuel the development of its promising drug for Duchenne muscular dystrophy (DMD). The company announced it had closed a US$57.2 million equity offering and commenced trading on the Nasdaq Global Market under the ticker “MSLE,” signaling a new phase of strategic growth and clinical execution.

This infusion of capital, which extends the company’s expected cash runway through 2027, comes at a pivotal moment. Satellos is advancing SAT-3247, a first-in-class oral drug candidate, through two critical Phase 2 clinical trials aimed at treating the debilitating muscle-wasting effects of Duchenne.

“2025 was a defining year for Satellos, and we are excited by the progress we have made across our clinical programs,” stated Satellos CEO Frank Gleeson in a recent announcement, highlighting the initiation of the BASECAMP pediatric study and the TRAILHEAD adult study. The company's recent financial and clinical milestones position it to deliver key data readouts later this year, which are being closely watched by investors and the patient community.

A New Strategy for a Growing Player

The dual achievements of a successful Nasdaq listing and substantial financing underscore a period of intense activity and strategic positioning for Satellos. The company’s shares began trading on the Nasdaq on February 6, 2026, a move designed to increase visibility and attract a broader base of U.S. and international investors. While the stock has seen volatility typical of newly listed biotechs, the successful financing, which priced shares at US$10.10, provides the financial stability needed for its ambitious clinical agenda.

This financial fortification is crucial, as the company’s 2025 results reflect the high cost of innovation in the biopharmaceutical sector. Satellos reported a net loss of $24.9 million for the year, an increase from $20.6 million in 2024. The rise was driven primarily by a jump in Research and Development (R&D) expenses to $18.4 million, directly linked to advancing SAT-3247 into more complex and costly clinical trials. Such spending is standard for clinical-stage companies, which often operate at a loss for years while investing heavily in bringing potential new medicines to market. With a strong solvency profile and no debt, the new funding places Satellos on solid ground to navigate the next two years of development.

Beyond Dystrophin: A New Scientific Approach to DMD

What sets SAT-3247 apart in the increasingly crowded DMD treatment landscape is its novel scientific mechanism. Current approved treatments, including exon-skipping drugs and the gene therapy Elevidys, primarily focus on restoring the production of dystrophin, the protein that is missing or defective in DMD patients. While transformative for some, these therapies are often limited to patients with specific genetic mutations.

Satellos is pursuing a fundamentally different and potentially complementary path. SAT-3247 is an oral small-molecule tablet designed to restore the body’s innate muscle regeneration capabilities by targeting a protein known as AAK1. In healthy individuals, muscle stem cells effectively repair and replace damaged muscle fibers. In DMD, this process is impaired. Satellos’ research suggests that by modulating AAK1, SAT-3247 can restore the proper function of these stem cells, enabling muscle to regenerate.

This approach is independent of dystrophin and a patient's specific mutation, meaning it could potentially benefit a much broader population of individuals living with DMD. Further bolstering its scientific platform, the company announced the validation of a novel “Regenerative Index” (RI), a biomarker developed to quantify the drug's effect on muscle regeneration. This RI is now being used as an exploratory endpoint in the pediatric trial, offering a potential way to measure treatment effect more directly.

From Adults to Children: Clinical Trials Show Promise

The real-world potential of SAT-3247 is being tested in two key human trials. The TRAILHEAD study is a 12-month, open-label trial in adults with DMD. At the recent Muscular Dystrophy Association (MDA) conference, Satellos presented encouraging interim data from four adult participants who had previously been in a shorter trial. After a gap in treatment, they re-enrolled in TRAILHEAD and received the drug for another 56 days. Results showed that handgrip strength improvements seen in the initial trial were maintained or even improved over a total period of 9 to 13 months. The data also showed preliminary signs of improvement in larger muscle groups, with greater effects observed in participants who had more muscle mass at the start of the study.

This promising adult data has increased confidence as Satellos embarks on its most critical study: BASECAMP. This global, randomized, placebo-controlled Phase 2 trial recently dosed its first participant and will evaluate SAT-3247 in 51 boys aged 7 to less than 10 years old. For the DMD community, where early intervention is seen as crucial to preserving long-term function, the initiation of a pediatric trial is a significant milestone. Satellos anticipates completing enrollment for BASECAMP in the third quarter of 2026, with top-line data expected in the fourth quarter.

Expanding Horizons Beyond Duchenne

Satellos is also looking beyond DMD, suggesting that its muscle regeneration platform could have broad applications. At the MDA conference, the company presented new preclinical data showing that SAT-3247 significantly enhanced muscle strength in an animal model of Facioscapulohumeral Muscular Dystrophy (FSHD), another progressive muscle-wasting disease.

FSHD affects tens of thousands of people and currently has no approved disease-modifying treatments, representing a significant unmet medical need. While still in early stages, this data suggests that SAT-3247 could one day offer hope to patients with other degenerative muscle conditions. For now, all eyes are on the progress of the DMD trials, as the company leverages its newfound financial strength to push toward its goal of delivering a life-improving medicine for a devastating disease.